文献速递血栓与止血

HMGB1-TLR4通路激活影响免疫性血小板减少症中骨髓间充质干细胞功能并破坏巨噬细胞极化

Activation of the HMGB1-TLR4 pathway impacts the functionality of bone marrow mesenchymal stem cells and disrupts macrophage polarization in immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2024-08-21

本研究探讨HMGB1通过TLR4-MyD88通路对免疫性血小板减少症(ITP)中骨髓间充质干细胞(BMSCs)功能及巨噬细胞极化失衡的调控作用。ITP患者存在单核/巨噬细胞极化失调和BMSCs功能受损,HMGB1在炎症因子存在时负向影响BMSCs调节巨噬细胞极化的能力,TLR4抑制剂可恢复该能力并抑制MyD88依赖通路激活,si-TLR4-BMSCs输注在ITP小鼠模型中逆转HMGB1诱导的血小板功能障碍并减少M1样巨噬细胞过度极化。

要点

  • ITP患者存在单核/巨噬细胞极化失调及BMSCs功能受损。
  • HMGB1在炎症因子存在时负向调控BMSCs纠正巨噬细胞极化失衡的能力。
  • TLR4抑制剂或si-TLR4-BMSCs可恢复BMSCs免疫调节功能并改善ITP小鼠血小板功能障碍。

核心结论

  • 靶向HMGB1-TLR4通路可能成为恢复BMSCs免疫调节功能的潜在途径。

研究设计与样本

  • 研究纳入ITP患者,观察单核/巨噬细胞极化及BMSCs功能,并探究HMGB1调控BMSCs生理功能与巨噬细胞极化失衡的关系。
  • 采用HMGB1处理BMSCs,检测MyD88依赖通路激活,并使用TLR4抑制剂及si-TLR4-BMSCs在ITP小鼠模型中进行干预。

主要发现

  • ITP患者表现为单核/巨噬细胞极化失调和BMSCs功能受损。
  • HMGB1对BMSCs调节巨噬细胞极化失衡的能力产生负面影响,尤其在炎症因子存在时。
  • HMGB1处理显著增强BMSCs下游MyD88依赖通路。
  • TLR4抑制剂成功恢复BMSCs改善巨噬细胞极化失衡的调控能力,并有效抑制MyD88依赖通路激活。
  • 在ITP小鼠模型中,输注si-TLR4-BMSCs逆转HMGB1诱导的血小板功能障碍,并减少向M1样巨噬细胞的过度极化。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent evidence suggests that immune thrombocytopenia (ITP), a common bleeding disorder, is linked to an imbalance in macrophage polarization and impaired bone marrow mesenchymal stem cells (BMSCs). However, the relationship between macrophage polarization imbalance and functional defects in BMSCs, as well as the involvement of associated molecules in BMSCs' defects, is not well understood. This study aimed to investigate the regulatory effects of high mobility group protein 1 (HMGB1) on the physiological functions of BMSCs, specifically in relation to macrophage polarization imbalance. Patients with ITP showed dysregulation in monocyte/macrophage polarization and impaired BMSCs function. HMGB1 was found to have a negative impact on the ability of BMSCs to regulate the imbalance in macrophage polarization, especially when inflammatory factors are present. The MyD88-dependent pathway downstream of BMSCs was found to be significantly enhanced with HMGB1 treatment. Furthermore, treatment with toll-like receptor 4 (TLR4) inhibitors successfully restored the regulatory capacity of BMSCs in ameliorating macrophage polarization imbalance and effectively inhibited the activation of the MyD88-dependent pathway. Meanwhile, infusion of si-TLR4-BMSCs reversed HMGB1-induced platelet dysfunction and reduced over-polarization to M1-like macrophages in the ITP mouse model. Consequently, targeting the HMGB1-TLR4 pathway could be a potential approach to restore the immunoregulatory function of BMSCs.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Liang Z, Zhang G, Gan G, et al. Activation of the HMGB1-TLR4 pathway impacts the functionality of bone marrow mesenchymal stem cells and disrupts macrophage polarization in immune thrombocytopenia. Br J Haematol. 2024. PMID: 39169447. doi:10.1111/bjh.19709

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。